CRL

Charles River Laboratories International Inc

Exchange: NYSESector: HealthcareIndustry: Diagnostics & Research

Charles River Laboratories International, Inc. is a global provider of solutions, which accelerate the early-stage drug discovery and development process. The focus of its business is in vivo biology; its portfolio includes research models and services required to enable in vivo drug discovery and development. The Company operates in two segments: Research Models and Services (RMS) and Preclinical Services (PCS). Through its RMS segment, the Company has been supplying research models to the drug development industry. The Company is engaged in the production and sale of rodent research model strains, principally genetically and microbiologically defined purpose-bred rats and mice. Its PCS business segment provides services that enable its clients to outsource their critical, regulatory-required safety assessment and related drug development activities to the Company. In August 2012, the Company acquired Accugenix, Inc. In January 2013, the Company acquired 75% ownership of Vital River.

Did you know?

Trading 4% above its estimated fair value of $161.69.

Current Price

$167.74

-9.23%

GoodMoat Value

$161.69

3.6% overvalued

Profile

Valuation (TTM)

Market Cap$8.26B

P/E-57.19

EV$10.13B

P/B2.61

Shares Out49.22M

P/Sales2.06

Revenue$4.02B

EV/EBITDA25.97

Charles River Laboratories International Inc (CRL) Financial Statements

GoodMoat Analysis

Based on data as of March 26, 2026

Charles River Laboratories presents a mixed financial picture for a value investor. While it generates a healthy free cash flow yield and maintains a manageable debt level, the company is currently unprofitable on a GAAP basis and shows concerning signs of revenue decline and weak operating leverage.

Read full analysis

The financial quality of Charles River Laboratories is currently unfavourable based on the framework's key indicators. The company is not GAAP profitable, reporting a negative EPS of -$2.91 and a profit margin of -3.6%, which fails the framework's profitability criterion. Revenue growth is also a concern, with a YoY decline of -0.8%, indicating a lack of consistent, sustainable growth. The operating margin of 0.6% is very thin, suggesting a lack of positive operating leverage where revenue growth outpaces expense growth. On a more positive note, the company demonstrates solid free cash flow generation with a 6.4% FCF yield, which exceeds the framework's >10-15% FCF margin threshold when considered as a percentage of market cap. The balance sheet shows moderate leverage with a Debt/Equity ratio of 0.81, which is below the framework's cautionary threshold of 1.0x Debt/EBITDA, though a full assessment requires the EBITDA figure. The negative ROE of -4.6% is well below the desired sustainable level of >15-20%. Overall, the profile is one of a cash-generative but currently unprofitable business experiencing top-line pressure. Analysis based on data as of 2024-05-15.

CRL Financial Data

EBITDA$408.66M

Revenue (TTM)$4.02B

Gross Profit (TTM)$1.32B

Gross Margin—

Operating Margin0.63%

ROE-4.56%

ROA-2.02%

Debt/Equity0.81

Current Ratio1.29

FCF$518.49M

FCF Yield6.28%

Piotroski F-Score—

Rev/Share (TTM)$81.59

50-Day MA$168.80

200-Day MA$175.68

Shares Outstanding0.05B

CRL Computed Insights

FCF$518.49M

FCF Growth Rate7.26%

EPS Growth (CAGR)-38.48%

WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

CRL Financial Statements & Data

Charles River Laboratories International Inc (CRL) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Charles River Laboratories International Inc's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $4.02B. Gross profit (TTM) is $1.32B. EBITDA is $408.66M. Earnings per share (EPS) is $-2.91. The P/E ratio is -57.19. Market capitalization is $8.26B.

Free cash flow (FCF) is $518.49M. FCF growth rate is 7.26%. EPS growth CAGR is -38.48%. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Charles River Laboratories International Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.